

Supporting Information

Palladium-Catalyzed Ring-Opening [5+2] Annulation of Vinylethylene Carbonates (VECs) and C5-substituted Meldrum's acids: Rapid synthesis of 7-Membered Lactones

Fei Li, Xin Chen, Ben-Qing Huang, Hua-Dong Xu, Chi-Fan Zhu* and Mei-Hua Shen*

School of Pharmacy, Changzhou University, Changzhou, Jiangsu Province 213164, China. E-mail:
chifanzhu@cczu.edu.cn, shenmh@cczu.edu.cn.

Table of Contents

1. General information -----	S2
2. Preparation of Substrates -----	S2-S5
3. Preparation and Characterization of the products -----	S5-S14
4. References -----	S14-15
5. Copies of ^1H and ^{13}C NMR spectra -----	S16-S48
6. Table S1-S4 Condition Optimization for Enantioselective Synthesis of Product 3a -----	S49-50
7. Spectroscopic Data of 3a (HPLC Trace) -----	S50-51


1. General Information and Materials

NMR spectra were recorded using Bruker AV-300 / AV-400/ AV-500 spectrometers. The data are reported as follows: chemical shift in ppm from internal tetramethylsilane on the δ scale, multiplicity (br = broad, s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd = doublet of doublets, dt = doublet of triplets, td = triplet of doublets), coupling constants (Hz) and integration. High resolution mass spectra were acquired on an agilent 6230 spectrometer and were obtained by peak matching. Analytical thin layer chromatography was performed on 0.25 mm extra hard silica gel plates with UV254 fluorescent indicator and/or by exposure to phosphormolybdic acid/cerium (IV) sulfate/ninhydrine followed by brief heating with a heat gun. Liquid chromatography (flash chromatography) was performed on 60 \AA (40-60 μm) mesh silica gel (SiO_2). All reactions were carried out under nitrogen with anhydrous solvents in oven-dried glassware, unless otherwise noted. All reagents were commercially obtained and, where appropriate, purified prior to use.

2. Preparation of Substrates

General procedure for synthesis of 4-phenyl-4-vinyl-1,3-dioxolan-2-one 1a-1j:

Prepared according to a previous reported procedure^[1-2]



Step 1: To a solution of PhI(OAc)₂ (1.5 equiv), KOH (2.5 equiv) in MeOH was added aryl acetophenone (1.0 equiv) under Ar at 0 °C. The reaction mixture was allowed to stir at 0 °C for 3 h. The reaction mixture was quenched by H₂O and extracted with EA (x 3). The combined organic layers were washed with brine, and then dried over anhydrous Na₂SO₄ and concentrated. The crude residue was purified by column chromatography.


Step 2: S1-2 (1 equiv) was dissolved in THF: H₂O (3: 1) with the addition of *p*-TsOH

(2 equiv). The mixture was heated to reflux for 4.5 h, monitored the reaction with TLC. Quenched the reaction with sat. NaHCO₃ and extracted the product with EtOAc (x 3). The combined organic extracts were washed with brine and dried over Na₂SO₄^[1]. After removal of the solvents under reduced pressure, the residue was purified by flash column chromatography (petroleum ether /EtOAc = 5/1 to 3/1) to afford substrates S1-3.

Step 3: To a solution of hydroxyl methyl ketone S1-3 (1 equiv.) in THF was added vinylmagnesium bromide (1.0 M in THF, 2.5 equiv.) at 0 °C. The reaction was stirred under N₂ atmosphere at room temperature for 2 h. The reaction mixture was then quenched with saturated aqueous NH₄Cl, and extracted with EtOAc. The combined organic layers were dried over anhydrous Na₂SO₄, filtered and concentrated. The crude residue was purified by column chromatography.

Step 4: To a solution of diol S1-3 (1 equiv.) and pyridine (4 equiv.) in CH₂Cl₂ was added triphosgene (0.5 equiv.) at 0 °C. The reaction was stirred under N₂ atmosphere at room temperature for 2 h. The reaction mixture was then quenched with saturated aqueous NH₄Cl, and extracted with CH₂Cl₂. The combined organic layers were dried over anhydrous Na₂SO₄, filtered and concentrated. The crude residue was purified by column chromatograph^[2].


General procedure for synthesis of (E)-4-styryl-4-vinyl-1,3-dioxolan-2-one 1k:



(E)-1-hydroxy-4-phenylbut-3-en-2-one (SM3) was synthesized according to the literature known procedure^[3] starting from (E)-4-phenylbut-3-en-2-one (SM1).

General procedure for synthesis of 2,2-dimethyl-5-phenyl-1,3-dioxane-4,6-dione (2s):


Prepared according to a previous reported procedure [4]



A round-bottom flask equipped with a stirring bar was charged with the malonic acid derivatives (1.0 equiv) and Ac₂O (5-8 M), and cooled to 0 °C (ice/water bath). After the addition of 2-3 drops of concentrated H₂SO₄, acetone (1.1 equiv) was added dropwise to the stirred mixture with a pressure-equalizing dropping funnel. The reaction was allowed to warm to room temperature and stirred for 6 h. Then, the resulting mixture was placed in the refrigerator for 2 h, and the resulting solid was collected by filtration on a fritted funnel and rinsed with cold water (2 times) and Et₂O (3 times). Traces of water were removed by addition of toluene (10 mL) and evaporation (3 times) to afford the desired product **2a**^[4].


General procedure for synthesis of 5-Aryl-2,2-dimethyl-1,3-dioxane-4,6-dione/ 5-alkyl-2,2-dimethyl-1,3-dioxane-4,6-dione 2a-2r,2t-2v

Prepared according to a previous reported procedure [5]




A round-bottom flask with a stir bar was flame-dried under vacuum and cooled under inert atmosphere. Meldrum's acid (1.0 equiv), Hantzsch ester (1.0 equiv), and proline (0.20 equiv) were added on the benchtop. The flask was evacuated and backfilled with N₂ (x3). EtOH (0.3 M) was added, followed by the aldehyde (1.0 equiv) and the reaction was left to stir overnight at room temperature. Upon completion of the reaction (as determined by TLC), the solution was concentrated under reduced pressure, diluted with EtOAc, and washed with 1M HCl. The aqueous layer was extracted with EtOAc (x2) and the combined organic layer was washed with brine (x1), dried over MgSO₄, and concentrated. The crude residue was purified by column chromatography^[5].


3. Preparation and Characterization of the products




A 10 mL Schlenk tube containing a stirring bar was charged with Pd₂(dba)₃ (0.1 equiv., 0.015 mmol), dppb (0.2 equiv., 0.03 mmol), substituted Meldrum's acid **2** (0.3 mmol), t-BuOK (2.0 equiv., 0.3 mmol). The tube was then evacuated and back-filled with argon three times. Then substituted vinyl ethylene carbonate **1** (0.15 mmol in 1mL anhydrous EA) was added to the tube under nitrogen atmosphere, and stirred at room temperature for 10 h. After the reaction was completed (monitored by TLC), the reaction mixture was filtered with diatomite and purified by column chromatography on silica gel (PE : EA = 20:1) to give the desired product.




3-benzyl-6-phenyl-4,7-dihydroxepin-2(3H)-one (3a) [6]: white solid, mp: 68-70°C, 34.2 mg, 82%. ¹H NMR (400 MHz, Chloroform-d) δ 7.25 (m, 4H), 7.22-7.14 (m, 6H), 5.81 (m, 1H), 5.32 (m, 1H), 4.71 (d, *J* = 15.6 Hz, 1H), 3.50 (m, 1H), 3.23 (m, 1H), 2.62 (m, 1H), 2.53 (m, 1H), 2.37 (m, 1H). ¹³C NMR (100 MHz, Chloroform-d) δ 175.7, 141.1, 138.9, 136.8, 129.3, 129.0, 128.6, 128.5, 127.6, 126.6, 126.2, 67.2, 41.3, 37.7, 32.1.




3-(2-fluorobenzyl)-6-phenyl-4,7-dihydroxepin-2(3H)-one (3b): white solid, mp: 119-121°C, 26.3 mg, 59%. ¹H NMR (400 MHz, Chloroform-d) δ 7.44-7.22 (m, 7H), 7.12 (m, 2H), 5.94 (m, 1H), 5.44 (m, 1H), 4.83 (d, *J* = 15.2 Hz, 1H), 3.71 (m, 1H), 3.29 (m, 1H), 2.87 (m, 1H), 2.72-2.43 (m, 2H). ¹³C NMR (100 MHz, Chloroform-d) δ 175.5, 162.6 (¹J_{CF} = 243.2 Hz), 141.1, 136.8, 132.3, 132.2, 128.9, 128.7, 128.6 (³J_{CF} = 8.2 Hz), 127.7, 126.2, 125.8, 125.6, 124.3 (⁴J_{CF} = 3.5 Hz), 115.3 (²J_{CF} = 21.8 Hz), 67.2, 39.7, 32.2, 31.5. HRMS (ESI⁺): calcd. for [C₁₉H₁₇FNaO₂]⁺: 319.1110, found: 319.1111.




3-(2-bromobenzyl)-6-phenyl-4,7-dihydrooxepin-2(3H)-one(3c): white solid, mp: 103-105°C, 32.7 mg, 61%. ¹H NMR (400 MHz, Chloroform-d) δ 7.61 (m, 1H), 7.48-7.23 (m, 7H), 7.17 (m, 1H), 5.95 (m, 1H), 5.43 (m, 1H), 4.82 (d, *J* = 15.2 Hz, 1H), 3.82 (m, 1H), 3.42 (m, 1H), 2.90 (m, 1H), 2.75-2.47 (m, 2H). ¹³C NMR (100 MHz, Chloroform-d) δ 175.5, 141.1, 138.1, 136.8, 133.0, 132.5, 129.0, 128.7, 128.6, 127.7, 127.6, 126.2, 124.8, 67.2, 39.2, 38.0, 32.2. HRMS (ESI⁺): calcd. for [C₁₉H₁₇BrNaO₂]⁺: 379.0310, found: 379.0305.



3-(3-fluorobenzyl)-6-phenyl-4,7-dihydrooxepin-2(3H)-one(3d): white solid, mp: 96-98°C, 27.8 mg, 63%. ¹H NMR (400 MHz, Chloroform-d) δ 7.43-7.25 (m, 6H), 7.10 (d, *J* = 7.6 Hz, 1H), 7.07-6.95 (m, 2H), 5.94 (m, 1H), 5.44 (m, 1H), 4.84 (d, *J* = 15.6 Hz, 1H), 3.72-3.54 (m, 1H), 3.33 (m, 1H). ¹³C NMR (100 MHz, Chloroform-d) δ 175.4, 164.1 (¹J_{CF} = 244.4 Hz), 141.5, 141.0, 136.9, 130.0 (³J_{CF} = 8.4 Hz), 128.8, 128.7, 127.7, 126.2, 125.1 (⁴J_{CF} = 2.9 Hz), 116.1 (²J_{CF} = 20.8 Hz), 113.70, 113.5, 77.3, 67.2, 41.1, 37.5, 37.4, 32.2. HRMS (ESI⁺): calcd. for [C₁₉H₁₇FNaO₂]⁺: 319.1110, found: 319.1106.




3-(3-bromobenzyl)-6-phenyl-2,3,4,7-tetrahydrooxepine(3e): white solid, mp: 84-86°C, 37.5 mg, 70%. ¹H NMR (400 MHz, Chloroform-d) δ 7.33 (d, *J* = 2.0 Hz, 1H), 7.32-7.02 (m, 8H), 5.80 (m, 1H), 5.30 (m, 1H), 4.70 (d, *J* = 15.6 Hz, 1H), 3.57-3.42 (m, 1H), 3.17 (m, 1H), 2.57 (m, 1H), 2.53-2.43 (m, 1H), 2.36 (m, 1H). ¹³C NMR (100 MHz, Chloroform-d) δ 175.4, 141.3, 141.0, 136.9, 132.3, 130.2, 129.8, 128.8, 128.7, 128.2, 127.7, 126.2, 122.6, 67.3, 41.2, 37.4, 32.2. HRMS (ESI⁺): calcd. for [C₁₉H₁₇BrNaO₂]⁺: 379.0310, found: 379.0306.




3-(4-fluorobenzyl)-6-phenyl-4,7-dihydrooxepin-2(3H)-one(3f): white solid, mp: 114-116°C, 25.8 mg, 58%. ¹H NMR (400 MHz, Chloroform-d) δ 7.38 (d, *J* = 7.2 Hz, 1H), 7.36-7.31 (m, 1H), 7.28 (m, 5H), 7.04 (m, 2H), 5.93 (m, 1H), 5.43 (m, 1H), 4.82


(d, $J = 15.6$ Hz, 1H), 3.57 (m, 1H), 3.30 (m, 1H), 2.71 (m, 1H), 2.63 (m, 1H), 2.49 (m, 1H). ^{13}C NMR (100 MHz, Chloroform-d) δ 175.5, 162.9 ($^1J_{\text{CF}} = 243.1$ Hz), 141.0, 136.9, 134.6 ($^4J_{\text{CF}} = 3.3$ Hz), 130.8 ($^3J_{\text{CF}} = 8$ Hz), 128.7 ($^2J_{\text{CF}} = 18.6$ Hz), 127.7, 126.2, 115.5, 115.3, 67.2, 41.5, 36.9, 32.2. HRMS (ESI $^+$): calcd. for [C₁₉H₁₇FNaO₂] $^+$: 319.1110, found: 319.1110.



3-(4-chlorobenzyl)-6-phenyl-4,7-dihydrooxepin-2(3H)-one(3g): white solid, mp: 113-115°C, 34.8 mg, 74%. ^1H NMR (400 MHz, Chloroform-d) δ 7.34 (m, 5H), 7.26 (m, 4H), 5.93 (m, 1H), 5.43 (m, 1H), 4.83 (d, $J = 15.2$ Hz, 1H), 3.58 (m, 1H), 3.29 (m, 1H), 2.71 (m, 1H), 2.62 (m, 1H), 2.57-2.39 (m, 1H). ^{13}C NMR (100 MHz, Chloroform-d) δ 175.4, 141.0, 137.4, 136.9, 132.5, 130.7, 128.8, 128.7, 128.6, 127.7, 126.2, 67.2, 41.3, 37.1, 32.2. HRMS (ESI $^+$): calcd. for [C₁₉H₁₇ClNaO₂] $^+$: 335.0815, found: 335.0813.




3-(4-bromobenzyl)-6-phenyl-4,7-dihydrooxepin-2(3H)-one(3h): white solid, mp: 98-100°C, 40.2 mg, 75%. ^1H NMR (400 MHz, Chloroform-d) δ 7.52-7.43 (m, 2H), 7.43-7.24 (m, 5H), 7.24-7.15 (m, 2H), 5.93 (m, 1H), 5.42 (m, 1H), 4.83 (d, $J = 15.2$ Hz, 1H), 3.64-3.51 (m, 1H), 3.28 (m, 1H), 2.70 (m, 1H), 2.66-2.57 (m, 1H), 2.49 (m, 1H). ^{13}C NMR (100 MHz, Chloroform-d) δ 175.4, 141.0, 137.9, 136.9, 131.7, 131.1, 128.8, 128.7, 127.7, 126.2, 120.5, 67.2, 41.3, 37.2, 32.2. HRMS (ESI $^+$): calcd. for [C₁₉H₁₇BrNaO₂] $^+$: 379.0310, found: 379.0311.




6-phenyl-3-(4-(trifluoromethyl)benzyl)-4,7-dihydrooxepin-2(3H)-one(3i): white solid, mp: 111-113°C, 32.2 mg, 62%. ^1H NMR (400 MHz, Chloroform-d) δ 7.62 (d, $J = 8.0$ Hz, 2H), 7.44 (d, $J = 8.0$ Hz, 2H), 7.41-7.25 (m, 5H), 5.93 (m, 1H), 5.42 (m, 1H), 4.83 (d, $J = 15.6$ Hz, 1H), 3.65 (m, 1H), 3.38 (m, 1H), 2.81 (m, 1H), 2.73-2.46 (m, 2H). ^{13}C NMR (100 MHz, Chloroform-d) δ 175.2, 143.1(0), 140.92 ($^1J_{\text{CF}} = 216$ Hz), 136.9, 129.7, 129.1, 128.7 ($^3J_{\text{CF}} = 5.6$ Hz), 128.6 ($^2J_{\text{CF}} = 17.7$ Hz), 127.8, 126.2, 125.6 ($^4J_{\text{CF}} =$


3.7Hz), 125.5(0), 125.4(6), 122.9, 67.2, 41.2, 37.6, 32.3. HRMS (ESI⁺): calcd. for [C₂₀H₁₇F₃NaO₂]⁺: 369.1078, found: 369.1081.




4-((2-oxo-6-phenyl-2,3,4,7-tetrahydrooxepin-3-yl)methyl)benzonitrile(3j): white solid, mp: 128-130°C, 36.4 mg, 82%. ¹H NMR (400 MHz, Chloroform-d) δ 7.57-7.48 (m, 2H), 7.33 (d, *J* = 8.0 Hz, 2H), 7.29-7.12 (m, 5H), 5.82 (m, 1H), 5.31 (m, 1H), 4.71 (d, *J* = 15.6 Hz, 1H), 3.60-3.49 (m, 1H), 3.25 (m, 1H), 2.69 (m, 1H), 2.58-2.36 (m, 2H). ¹³C NMR (100 MHz, Chloroform-d) δ 175.0, 144.6, 140.8, 137.0, 132.4, 130.2, 128.7, 128.4, 127.8, 126.2, 118.9, 110.6, 67.3, 41.1, 37.9, 32.5. HRMS (ESI⁺): calcd. for [C₂₀H₁₇NNaO₂]⁺: 326.1157, found: 326.1154.




3-(4-nitrobenzyl)-6-phenyl-4,7-dihydrooxepin-2(3H)-one(3k): white solid, mp: 137-139°C, 30.1 mg, 62%. ¹H NMR (400 MHz, Chloroform-d) δ 8.21 (d, *J* = 8.0 Hz, 2H), 7.50 (d, *J* = 8.4 Hz, 2H), 7.42-7.24 (m, 5H), 5.94 (m, 1H), 5.42 (m, 1H), 4.84 (d, *J* = 15.2 Hz, 1H), 3.68 (m, 1H), 3.41 (m, 1H), 2.86 (m, 1H), 2.61 (m, 2H). ¹³C NMR (100 MHz, Chloroform-d) δ 174.9, 146.8, 146.7, 140.8, 137.0, 130.3, 128.7, 128.4, 127.8, 126.2, 123.8, 67.3, 41.2, 37.7, 32.5. HRMS (ESI⁺): calcd. for [C₁₉H₁₇NNaO₄]⁺: 346.1055, found: 346.1054.




Methyl 4-((2-oxo-6-phenyl-2,3,4,7-tetrahydrooxepin-3-yl)-methyl)benzoate(3l): white solid, mp: 109-111°C, 33.8 mg, 67%. ¹H NMR (400 MHz, Chloroform-d) δ 8.04 (d, *J* = 8.0 Hz, 2H), 7.47-7.20 (m, 7H), 5.92 (m, 1H), 5.43 (m, 1H), 4.83 (d, *J* = 15.2 Hz, 1H), 3.95 (s, 3H), 3.66 (m, 1H), 3.37 (m, 1H), 2.80 (m, 1H), 2.71-2.42 (m, 2H). ¹³C NMR (100MHz, Chloroform-d) δ 175.0, 167.0, 144.4, 140.9, 136.9, 129.9, 129.4, 128.7, 128.7, 128.6, 127.7, 126.2, 67.2, 52.2, 41.1, 37.8, 32.3. HRMS (ESI⁺): calcd. for [C₂₁H₂₀NaO₄]⁺: 359.1259, found: 359.1254.




3-(2-methylbenzyl)-6-phenyl-4,7-dihydrooxepin-2(3H)-one(3m): white solid, mp: 138-140°C, 30.4 mg, 67%. ¹H NMR (400 MHz, Chloroform-d) δ 7.28-7.18 (m, 3H), 7.18-7.06 (m, 6H), 5.80 (m, 1H), 5.30 (m, 1H), 4.71 (d, *J* = 15.6 Hz, 1H), 3.48 (m, 1H), 3.20 (m, 1H), 2.66 (m, 1H), 2.52 (m, 1H), 2.40 (m, 1H), 2.29 (s, 3H). ¹³C NMR (100 MHz, Chloroform-d) δ 175.9, 141.1, 137.0, 136.7, 136.5, 130.6, 130.0, 129.1, 128.7, 127.7, 126.8, 126.2, 126.1, 67.3, 39.8, 34.7, 32.0, 19.8. HRMS (ESI⁺): calcd. for [C₂₀H₂₀NaO₂]⁺: 315.1361, found: 315.1362.



3-(3-methylbenzyl)-6-phenyl-4,7-dihydrooxepin-2(3H)-one(3n): white solid, mp: 91-93°C, 26.6 mg, 60%. ¹H NMR (400 MHz, Chloroform-d) δ 7.36 (m, 2H), 7.28 (m, 4H), 7.11 (d, *J* = 8.78 Hz, 3H), 5.93 (m, 1H), 5.44 (m, 1H), 4.83 (d, *J* = 15.2 Hz, 1H), 3.60 (m, 1H), 3.31 (m, 1H), 2.74-2.66 (m, 1H), 2.62 (m, 1H), 2.57-2.42 (m, 1H), 2.40 (s, 3H). ¹³C NMR (100 MHz, Chloroform-d) δ 175.9, 141.1, 138.8, 138.3, 136.7, 130.2, 129.2, 128.7, 128.5, 127.7, 127.4, 126.4, 126.2, 67.3, 41.3, 37.7, 32.1, 21.5. HRMS (ESI⁺): calcd. for [C₂₀H₂₀NaO₂]⁺: 315.1361, found: 315.1359.




3-(3-methoxybenzyl)-6-phenyl-4,7-dihydrooxepin-2(3H)-one(3o): white solid, mp: 97-99°C, 29.2 mg, 63%. ¹H NMR (400 MHz, Chloroform-d) δ 7.30-7.11 (m, 6H), 6.81-6.67 (m, 3H), 5.80 (m, 1H), 5.31 (m, 1H), 4.70 (d, *J* = 15.2 Hz, 1H), 3.74 (s, 3H), 3.49 (m, 1H), 3.20 (m, 1H), 2.63-2.44 (m, 2H), 2.35 (m, 1H). ¹³C NMR (100 MHz, Chloroform-d) δ 175.8, 159.7, 141.1, 140.5, 136.7, 129.6, 129.1, 128.7, 127.7, 126.2, 121.7, 115.3, 111.7, 67.3, 55.3, 41.2, 37.7, 32.1. HRMS (ESI⁺): calcd. for [C₂₀H₂₀NaO₃]⁺: 331.1310, found: 331.1313.




3-(4-methylbenzyl)-6-phenyl-4,7-dihydrooxepin-2(3H)-one(3p): white solid, mp: 92-94°C, 27.7 mg, 63%. ¹H NMR (400 MHz, Chloroform-d) δ 7.36 (m, 3H), 7.31-7.25 (m, 2H), 7.20 (m, 4H), 5.93 (m, 1H), 5.44 (m, 1H), 4.83 (d, *J* = 15.6 Hz, 1H), 3.60 (m, 1H), 3.31 (m, 1H), 2.75-2.58 (m, 2H), 2.48 (m, 1H), 2.39 (s, 3H). ¹³C NMR (100 MHz, Chloroform-d) δ 175.9, 141.1, 136.7, 136.2, 135.8, 129.3, 129.2(5), 129.2, 128.7, 127.6, 126.2, 67.2, 41.4, 37.3, 32.1, 21.1. HRMS (ESI⁺): calcd. for [C₂₀H₂₀NaO₂]⁺: 315.1361,


found: 315.1361.




3-([1,1'-biphenyl]-4-ylmethyl)-6-phenyl-4,7-dihydrooxepin-2(3H)-one(3q): white solid, mp: 133-135°C, 32.4 mg, 61%. ^1H NMR (400 MHz, Chloroform-d) δ 7.72-7.62 (m, 4H), 7.56-7.25 (m, 10H), 5.97 (m, 1H), 5.48 (m, 1H), 4.86 (d, J = 15.2 Hz, 1H), 3.68 (m, 1H), 3.41 (m, 1H), 2.90-2.65 (m, 2H), 2.55 (m, 1H). ^{13}C NMR (100 MHz, Chloroform-d) δ 175.7, 141.1, 140.8, 139.6, 138.0, 136.8, 129.8, 129.1, 128.8, 128.7, 127.7, 127.4, 127.3, 127.1, 126.2, 67.3, 41.3, 37.4, 32.2. HRMS (ESI $^+$): calcd. for [C₂₅H₂₂NaO₂] $^+$: 377.1517, found: 377.1518.



3-(naphthalen-2-ylmethyl)-6-phenyl-4,7-dihydrooxepin-2(3H)-one(3r): white solid, mp: 131-133°C, 24.9 mg, 51%. ^1H NMR (400 MHz, Chloroform-d) δ 7.87 (m, 3H), 7.76 (s, 1H), 7.51 (m, 2H), 7.44 (d, J = 8.4 Hz, 1H), 7.41-7.24 (m, 5H), 5.91 (m, 1H), 5.44 (m, 1H), 4.84 (d, J = 15.2 Hz, 1H), 3.71 (m, 1H), 3.51 (m, 1H), 2.91 (m, 1H), 2.67 (m, 1H), 2.54 (m, 1H). ^{13}C NMR (100 MHz, Chloroform-d) δ 175.8, 141.1, 136.8, 136.4, 133.5, 132.3, 129.0, 128.67, 128.3, 127.9, 127.8, 127.7, 127.6(1), 127.6(0), 126.3, 126.2, 125.7, 67.3, 41.31, 37.9, 32.2. HRMS (ESI $^+$): calcd. for [C₂₃H₂₀NaO₂] $^+$: 351.1361, found: 351.1360.




3,6-diphenyl-4,7-dihydrooxepin-2(3H)-one(3s): white solid, mp: 113-115°C, 26.2 mg, 66%. ^1H NMR (400 MHz, Chloroform-d) δ 7.31-7.21 (m, 10H), 5.96 (m, 1H), 5.42 (m, 1H), 4.81 (d, J = 15.6 Hz, 1H), 4.59-4.45 (m, 1H), 2.98 (m, 1H), 2.73 (m, 1H). ^{13}C NMR (100 MHz, Chloroform-d) δ 174.3, 141.0, 137.7, 137.0, 128.8, 128.7, 128.6, 128.4, 127.8, 126.3, 117.7, 67.7, 45.5, 33.5. HRMS (ESI $^+$): calcd. for [C₁₈H₁₆NaO₂] $^+$: 287.1048, found: 287.1042.




6-phenyl-3-(3-phenylpropyl)-4,7-dihydrooxepin-2(3H)-one(3t): white solid, mp: 70-72°C, 22.4 mg, 52%. ^1H NMR (400 MHz, Chloroform-d) δ 7.27-7.19 (m, 4H), 7.19-7.13 (m, 3H), 7.13-7.07 (m, 3H), 5.80 (m, 1H), 5.22 (m, 1H), 4.66 (d, J = 15.6 Hz, 1H),

3.16 (m, 1H), 2.68-2.43 (m, 3H), 2.29 (m, 1H), 1.87 (m, 1H), 1.73 (m, 1H), 1.67-1.44 (m, 1H), 1.36 (m, 1H). ^{13}C NMR (100 MHz, Chloroform-d) δ 176.0, 142.1, 141.2, 136.8, 129.2, 128.7, 128.5, 128.4, 127.7, 126.2, 125.9, 67.1, 39.3, 36.0, 33.0, 31.6, 29.1. HRMS (ESI $^+$): calcd. for [C₂₁H₂₂NaO₂] $^+$: 329.1517, found: 329.1518.




(Z)-6-phenyl-3-(3-phenylallyl)-4,7-dihydroxepin-2(3H)-one(3u): white solid, mp: 113-115°C, 26.4 mg, 63%. ^1H NMR (400 MHz, Chloroform-d) δ 7.29 (m, 2H), 7.27-7.10 (m, 8H), 6.42 (d, J = 16.0 Hz, 1H), 6.19 (m, 1H), 5.85 (m, 1H), 5.41-5.26 (m, 1H), 4.72 (d, J = 15.2 Hz, 1H), 3.47-3.27 (m, 1H), 2.84-2.68 (m, 1H), 2.62 (m, 1H), 2.42-2.34 (m, 1H), 2.34-2.21 (m, 1H). ^{13}C NMR (100 MHz, Chloroform-d) δ 175.7, 141.1, 137.2, 136.9, 133.0, 129.1, 128.7, 128.6, 127.7, 127.4, 126.8, 126.3, 126.2, 67.3, 39.6, 35.3, 32.3.


HRMS (ESI $^+$): calcd. for [C₂₁H₂₀NaO₂] $^+$: 327.1361, found: 327.1363.




Ethyl 2-(2-oxo-6-phenyl-2,3,4,7-tetrahydroxepin-3-yl)acetate(3v): white solid, mp: 69-71°C, 30.6 mg, 74%. ^1H NMR (400 MHz, Chloroform-d) δ 7.43-7.28 (m, 5H), 5.96 (m, 1H), 5.54 (m, 1H), 4.87 (d, J = 15.6 Hz, 1H), 4.21 (m, 2H), 3.94 (m, 1H), 2.99 (m, 1H), 2.65 (m, 1H), 2.57-2.42 (m, 2H), 1.32 (t, J = 7.2 Hz, 3H). ^{13}C NMR (100 MHz, Chloroform-d) δ 175.3, 171.7, 141.0, 137.1, 128.7, 128.4, 127.7, 126.3, 67.4, 61.0, 36.5, 36.0, 32.0, 14.2. HRMS (ESI $^+$): calcd. for [C₁₆H₁₈NaO₄] $^+$: 297.1103, found: 297.1106.




3-benzyl-6-(2-chlorophenyl)-4,7-dihydroxepin-2(3H)-one(3w): white solid, mp: 110-112°C, 29.6 mg, 63%. ^1H NMR (400 MHz, Chloroform-d) δ 7.38-7.30 (m, 3H), 7.30-7.24 (m, 3H), 7.24-7.16 (m, 3H), 5.78 (m, 1H), 5.42 (m, 1H), 4.51 (d, J = 15.2 Hz, 1H), 3.63 (m, 1H), 3.31 (m, 1H), 2.70 (m, 1H), 2.62 (m, 1H), 2.42 (m, 1H). ^{13}C NMR (100 MHz, Chloroform-d) δ 175.7, 140.8, 138.9, 136.2, 132.1, 131.9, 130.5, 129.6, 129.4, 129.1, 128.6, 127.1, 126.7, 66.8, 41.1, 37.8, 32.1. HRMS (ESI $^+$): calcd. for [C₁₉H₁₇ClNaO₂] $^+$: 335.0815, found: 335.0817.




3-benzyl-6-(3-chlorophenyl)-4,7-dihydrooxepin-2(3H)-one(3x): white solid, mp: 70-72°C, 32.8 mg, 70%. ¹H NMR (400 MHz, Chloroform-d) δ 7.24 (m, 2H), 7.15 (m, 6H), 7.01 (m, 1H), 5.80 (m, 1H), 5.27 (m, 1H), 4.61 (d, *J* = 15.2 Hz, 1H), 3.47 (m, 1H), 3.20 (m, 1H), 2.66-2.43 (m, 2H), 2.43-2.25 (m, 1H). ¹³C NMR (100 MHz, Chloroform-d) δ 175.5, 142.8, 138.8, 135.7, 134.5, 130.3, 129.9, 129.4, 128.7, 127.7, 126.7, 126.5, 124.3, 66.8, 41.2, 37.7, 32.1. HRMS (ESI⁺): calcd. for [C₁₉H₁₇ClNaO₂]⁺: 335.0815, found: 335.0817.




3-benzyl-6-(4-bromophenyl)-4,7-dihydrooxepin-2(3H)-one(3y) ^[6]: white solid, mp: 106-108°C, 32.2 mg, 60%. ¹H NMR (400 MHz, Chloroform-d) δ 7.49 (d, *J* = 8.4 Hz, 2H), 7.37 (m, 2H), 7.34-7.25 (m, 4H), 7.14 (d, *J* = 8.4 Hz, 2H), 5.93 (m, 1H), 5.42 (m, 1H), 4.75 (d, *J* = 15.2 Hz, 1H), 3.67-3.54 (m, 1H), 3.34 (m, 1H), 2.73 (m, 1H), 2.64 (m, 1H), 2.47 (m, 1H). ¹³C NMR (100 MHz, Chloroform-d) δ 175.5, 139.9, 138.8, 135.8, 131.8, 129.7, 129.3, 128.7, 127.9, 126.7, 121.7, 66.9, 41.2, 37.7, 32.1.




3-benzyl-6-(m-tolyl)-4,7-dihydrooxepin-2(3H)-one(3z) ^[6]: white solid, mp: 94-96°C, 28.8 mg, 65%. ¹H NMR (400 MHz, Chloroform-d) δ 7.41-7.26 (m, 5H), 7.18 (s, 4H), 5.89 (m, 1H), 5.42 (m, 1H), 4.82 (d, *J* = 15.2 Hz, 1H), 3.61 (m, 1H), 3.35 (m, 1H), 2.74 (m, 1H), 2.63 (m, 1H), 2.48 (m, 1H), 2.38 (s, 3H). ¹³C NMR (100 MHz, Chloroform-d) δ 175.9, 138.9, 138.2, 137.5, 136.5, 129.4, 129.3, 128.6, 128.2, 126.6, 126.1, 67.3, 41.3, 37.7, 32.1, 21.1.




3-benzyl-6-(p-tolyl)-4,7-dihydrooxepin-2(3H)-one(3aa) ^[6]: white solid, mp: 94-96°C, 34.1 mg, 77%. ¹H NMR (400 MHz, Chloroform-d) δ 7.39 (m, 2H), 7.35-7.23 (m, 4H), 7.20-7.03 (m, 3H), 5.92 (m, 1H), 5.43 (m, 1H), 4.83 (d, *J* = 15.6 Hz, 1H), 3.72-3.55 (m, 1H), 3.36 (m, 1H), 2.75 (m, 1H), 2.65 (m, 1H), 2.49 (m, 1H), 2.39 (s, 3H). ¹³C NMR (100 MHz, Chloroform-d) δ 175.9, 141.1, 138.9, 138.3, 136.8, 129.4, 128.8, 128.6, 128.6, 128.4, 127.0, 126.7, 123.3, 67.3, 41.3, 37.8, 32.1, 21.5.




3-benzyl-6-(4-methoxyphenyl)-4,7-dihydrooxepin-2(3H)-one(3ab) [6]: white solid, mp: 93-95°C, 34.6 mg, 75%. ¹H NMR (400 MHz, Chloroform-d) δ 7.38 (m, 2H), 7.34-7.25 (m, 3H), 7.22 (d, *J* = 8.4 Hz, 2H), 6.90 (d, *J* = 8.4 Hz, 2H), 5.85 (m, 1H), 5.40 (m, 1H), 4.81 (d, *J* = 15.2 Hz, 1H), 3.84 (s, 3H), 3.69-3.52 (m, 1H), 3.34 (m, 1H), 2.73 (m, 1H), 2.62 (m, 1H), 2.48 (m, 1H). ¹³C NMR (100 MHz, Chloroform-d) δ 175.9, 159.2, 139.0, 136.2, 133.5, 129.4, 128.6, 127.6, 127.5, 126.6, 114.0, 67.3, 55.4, 41.3, 37.7, 32.1.



3-benzyl-6-(naphthalen-2-yl)-4,7-dihydrooxepin-2(3H)-one(3ac) [6]: white solid, mp: 113-115°C, 30.0 mg, 61%. ¹H NMR (400 MHz, Chloroform-d) δ 7.84-7.72 (m, 3H), 7.65 (d, *J* = 2.0 Hz, 1H), 7.50-7.42 (m, 2H), 7.40-7.30 (m, 3H), 7.26 (m, 3H), 5.99 (m, 1H), 5.44 (m, 1H), 4.90 (d, *J* = 15.2 Hz, 1H), 3.61 (m, 1H), 3.31 (m, 1H), 2.70 (m, 1H), 2.67-2.57 (m, 1H), 2.47 (m, 1H). ¹³C NMR (100 MHz, Chloroform-d) δ 175.8, 138.9, 138.3, 136.7, 133.3, 132.7, 129.6, 129.4, 128.7, 128.4, 128.0, 127.7, 126.7, 126.6, 126.2, 125.0, 124.4, 67.2, 41.3, 37.8, 32.2.




3-benzyl-6-(furan-2-yl)-4,7-dihydrooxepin-2(3H)-one(3ad) [6]: white solid, mp: 71-73°C, 22.5 mg, 56%. ¹H NMR (400 MHz, Chloroform-d) δ 7.36-7.29 (m, 2H), 7.24 (m, 3H), 7.16 (m, 1H), 7.00-6.89 (m, 2H), 6.09 (m, 1H), 5.32 (m, 1H), 4.89 (d, *J* = 15.2 Hz, 1H), 3.52 (m, 1H), 3.29 (m, 1H), 2.68 (m, 1H), 2.57 (m, 1H), 2.44 (m, 1H). ¹³C NMR (100 MHz, Chloroform-d) δ 175.5, 143.5, 138.8, 130.2, 129.3, 128.7, 127.7, 127.2, 126.7, 124.6, 123.0, 66.4, 41.2, 37.6, 31.8.




3-benzyl-6-(thiophen-2-yl)-4,7-dihydrooxepin-2(3H)-one(3ae) [6]: white solid, mp: 83-85°C, 22.2 mg, 52%. ¹H NMR (400 MHz, Chloroform-d) δ 7.26-7.20 (m, 3H), 7.18-7.14 (m, 3H), 6.29 (m, 1H), 6.18 (m, 1H), 6.15 (d, *J* = 3.6 Hz, 1H), 5.14 (m, 1H), 4.73 (d, *J* = 15.2 Hz, 1H), 3.44 (m, 1H), 3.20 (m, 1H), 2.60 (m, 1H), 2.56-2.48 (m, 1H), 2.41-2.31 (m, 1H). ¹³C NMR (100 MHz, Chloroform-d) δ 175.6, 152.1, 142.4, 138.8,

129.3, 128.6, 126.7, 126.3, 125.0, 111.4, 105.4, 64.0, 41.2, 37.7, 31.5.



(E)-3-benzyl-6-styryl-4,7-dihydrooxepin-2(3H)-one(3af) [6]: white solid, mp: 132–134°C, 25.1 mg, 55%. ¹H NMR (400 MHz, Chloroform-d) δ 7.39–7.35 (m, 2H), 7.32 (m, 4H), 7.26–7.21 (m, 4H), 6.65 (d, *J* = 16.4 Hz, 1H), 6.42 (d, *J* = 16.4 Hz, 1H), 5.88 (m, 1H), 5.13 (m, 1H), 4.92 (d, *J* = 14.8 Hz, 1H), 3.49 (m, 1H), 3.28 (m, 1H), 2.67 (m, 1H), 2.57 (m, 1H), 2.43 (m, 1H). ¹³C NMR (100 MHz, Chloroform-d) δ 175.8, 138.8, 136.8, 134.0, 131.7, 129.7, 129.3, 128.8, 128.6, 127.8, 126.8, 126.7, 126.4, 63.4, 41.2, 37.6, 32.0.



(E)-5-(4-hydroxy-3-phenylbut-2-en-1-yl)-2,2-dimethyl-5-phenyl-1,3-dioxane-4,6-dione(4s): white solid; ¹H NMR (400 MHz, Chloroform-d) δ 7.47–7.32 (m, 7H), 7.29–7.24 (m, 2H), 7.22–7.19 (m, 1H), 5.72 (t, *J* = 8.0 Hz, 1H), 4.48 (s, 2H), 3.22 (d, *J* = 8.0 Hz, 2H), 2.53 (s, 1H), 1.63 (s, 3H), 1.21 (s, 3H). ¹³C NMR (100 MHz, Chloroform-d) δ 166.6, 143.9, 141.0, 135.1, 130.0, 129.3, 128.4, 127.6, 126.5, 126.1, 124.2, 106.1, 60.8, 60.2, 40.5, 29.2, 27.6. HRMS (ESI⁺): calcd. for [C₂₂H₂₂NaO₅]⁺: 389.1365, found: 389.1366.


4. References

- [1] S. C. Sahoo, U. Nath and S. C. Pan, Direct Aerobic Oxidative Reactions of 2-Hydroxyacetophenones, *Eur. J. Org. Chem.*, 2017, **30**, 4434-4438.
- [2] C. H. Yuan, Y. Wu, D. Q. Wang, Z. H. Zhang, C. Wang, L. J. Zhou, C. Zhang, B. A. Song and H. C. Guo, Formal [5+3] Cycloaddition of Zwitterionic Allylpalladium Intermediates with Azomethine Imines for Construction of N, O-Containing Eight-Membered Heterocycles, *Adv. Synth. Catal.*, 2018, **360**, 652 – 658.
- [3] S. Lee, C. J. Lim, S. Kim, R. Subramaniam, J. Zimmerman, and M. P. Sibi. Enantioselective Conjugate Radical Addition to α' -Hydroxy Enones, *Org. Lett.*, 2006, **8**, 4311-4313.
- [4] T. Xavier, S. Condon, C. Pichon, E. L. Gall and M. Presset, Preparation of mono-substituted malonic acid half oxyesters (SMAHOs), *Beilstein J. Org. Chem.*, 2021, **17**, 2085–2094.
- [5] A. L. Gabbe, N. W. M. Michel, J. M. E. Hughes, L.-C. Campeau and S. A. L. Rousseaux., Synthesis of a-Aryl Secondary Amides via Nickel-Catalyzed Reductive Coupling of Redox-Active Esters, *Org. Lett.*, 2022, **24**, 3173–3178.


[6] S. Singha, T. Patra, C. G. Daniliuc and F. Glorius, *J. Am. Chem. Soc.*, 2018, **140**, 3551-3554.

5. Copies of ^1H and ^{13}C NMR spectra


^1H NMR of 3a




^{13}C NMR of 3a




¹H NMR of 3b




¹³C NMR of 3b




¹H NMR of 3c




¹³C NMR of 3c




¹H NMR of 3d




¹³C NMR of 3d




¹H NMR of 3e




¹³C NMR of 3e




¹H NMR of 3f




¹³C NMR of 3f




¹H NMR of 3g




¹³C NMR of 3g




¹H NMR of 3h




¹³C NMR of 3h




¹H NMR of 3i




¹³C NMR of 3i




¹H NMR of 3j




¹³C NMR of 3j




¹H NMR of 3k




¹³C NMR of 3k




¹H NMR of 3l




¹³C NMR of 3l




¹H NMR of 3m




¹³C NMR of 3m




¹H NMR of 3n




¹³C NMR of 3n




¹H NMR of 3o




¹³C NMR of 3o




¹H NMR of 3p




¹³C NMR of 3p




¹H NMR of 3q




¹³C NMR of 3q




¹H NMR of 3r




¹³C NMR of 3r




¹H NMR of 3s




¹³C NMR of 3s




¹H NMR of 3t




¹³C NMR of 3t




¹H NMR of 3u




¹³C NMR of 3u




¹H NMR of 3v




¹³C NMR of 3v




¹H NMR of 3w




¹³C NMR of 3w




¹H NMR of 3x




¹³C NMR of 3x





¹H NMR of 3y




¹³C NMR of 3y




¹H NMR of 3z




¹H NMR of 3aa




¹³C NMR of 3aa




¹H NMR of 3ab




¹³C NMR of 3ab




¹H NMR of 3ac




¹³C NMR of 3ac




¹H NMR of 3ad




¹³C NMR of 3ad




¹H NMR of 3ae




¹³C NMR of 3ae




¹¹H NMR of 3af



¹³C NMR of 3af



¹H NMR of 4s



¹³C NMR of 4s




Table S1. Chiral Brønsted bases Screening




Table S2. Chiral phosphine ligands Screening





Table S3. Screening for the combination of Chiral Brønsted bases and phosphine ligands




Example for the enantioselective synthesis of **3a**:

A 10 mL Schlenk tube containing a stirring bar was charged with $\text{Pd}_2(\text{dba})_3$ (0.1 equiv., 0.015 mmol), dppb (0.2 equiv., 0.03 mmol), substituted Meldrum's acid **2** (0.3 mmol), chiral Brønsted base **C1** (20 mol %, 0.03 mmol). The tube was then evacuated and back-filled with argon three times. Then substituted vinylethylene carbonate **1** (0.15 mmol in 1mL anhydrous EA) was added to the tube under nitrogen atmosphere, and stirred at room temperature for 10 h. After the reaction was completed (monitored by TLC), the reaction mixture was filtered with diatomite and purified by column chromatography on silica gel (PE : EA = 20:1) to give the desired product.


6. Spectroscopic Data of **3a** (HPLC Trace)

3-benzyl-6-phenyl-4,7-dihydroxepin-2(3H)-one(3a)




19.2 mg, 46% yield;

HPLC 45% ee, analysis: (Chiralcel OD-H, hexane/*i*-PrOH = 80/20, flow rate = 1.0 mL/min, λ = 254 nm), t_R = 8.5 min (minor), t_R = 9.7 min(major).



totals 2332.87073 75.23528

Chiral HPLC spectrum of racemic 3a



totals 4987.56628 143.70518

Chiral HPLC spectrum of 3a